December 29, 2017 / 12:59 PM / 9 months ago

BRIEF-Avadel Pharmaceuticals Issues 2018 Corporate Outlook

Dec 29 (Reuters) - Avadel Pharmaceuticals Plc:

* AVADEL PHARMACEUTICALS ISSUES 2018 CORPORATE OUTLOOK

* REAFFIRMS FY 2017 ADJUSTED EARNINGS PER SHARE VIEW $0.25 TO $0.35

* SEES FY 2017 REVENUE $165 MILLION TO $175 MILLION

* - ‍NDA FILING FOR FT218 EXPECTED BY YEAR-END 2018​

* - COMMERCIAL LAUNCH FOR NOCTIVA ON TARGET FOR Q2 2018

* FY2017 EARNINGS PER SHARE VIEW $1.48, REVENUE VIEW $171.8 MILLION -- THOMSON REUTERS I/B/E/S

* AVADEL PHARMACEUTICALS- AV001 IS EXPECTED TO COMPETE IN AN ESTIMATED MARKET SIZE OF ABOUT $30 - $40 MILLION PER YEAR ONCE LAUNCHED IN 2019

* - EXPECTS NEGATIVE CASH FLOW IN 2018

* - ‍ASSESSING TAX CUTS AND JOBS ACT OF 2017 AND, ACCORDINGLY, IS UNABLE TO PROVIDE 2018 ADJUSTED DILUTED EPS GUIDANCE​

* AVADEL PHARMACEUTICALS - ESTIMATES THAT PEAK REVENUES FOR NOCTIVA COULD BE AS HIGH AS $750 MILLION OR MORE PER YEAR Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below